Beta-catenin Translocation Modulation via Membrane Potential
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies face challenges in effectively targeting β-catenin translocation, a key step in various diseases such as cancer, diabetes, and osteoporosis, due to the complex and poorly understood mechanisms of Wnt signaling pathways, particularly the canonical and non-canonical pathways, which were thought to operate independently.
Innovation Solution
The discovery that Wnt/Ca2+ and Wnt/β-catenin pathways act in a coordinated manner, with modulation of cell membrane electrical potential facilitating β-catenin entry into the nucleus, allowing for the use of compounds like Dofetilide to regulate β-catenin translocation by altering ion transport across the cell membrane.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies target downstream intracellular kinases or Wnt receptors to inhibit β-catenin translocation, then disease progression may be slowed, but the complexity of the Wnt signaling pathway with multiple receptors and ligands makes effective targeting difficult
Solution Approach 1:
The patent uses membrane potential as an intermediary mechanism to control β-catenin translocation. Instead of directly targeting the complex Wnt signaling components, the invention modulates membrane potential (an intermediate physiological parameter) to indirectly regulate β-catenin nuclear entry, thereby simplifying the therapeutic approach while maintaining effectiveness
Solution Approach 2:
The invention changes the physical parameter of membrane potential to control β-catenin translocation. By altering the electrical state of the cell membrane through ion channel modulation, the patent achieves regulation of β-catenin nuclear translocation without needing to directly interfere with the complex molecular interactions of the Wnt pathway
2Reliability
If Wnt signaling is inhibited to treat cancer and diabetes, then pathological β-catenin translocation is reduced, but beneficial processes such as bone formation that depend on Wnt signaling may be impaired
Solution Approach 1:
The patent employs dynamic modulation of membrane potential to achieve context-dependent regulation of β-catenin translocation. By dynamically adjusting the electrical state of cells, the therapy can selectively inhibit pathological translocation in cancer and diabetic cells while preserving physiological translocation in bone-forming cells, thereby maintaining adaptability across different tissue types
Solution Approach 2:
The invention applies local quality control by allowing different cells to maintain their natural β-catenin translocation patterns based on their specific physiological needs. Membrane potential modulation creates locally differentiated effects: pathological cells experience inhibited translocation while physiological cells maintain normal function, enabling selective therapy without systemic suppression of beneficial Wnt signaling
3Measurement precision
If the mechanisms of β-catenin translocation are investigated in detail to develop targeted therapies, then treatment specificity may be improved, but the time and resources required for research and development increase
Solution Approach 1:
The patent extracts the essential control mechanism (membrane potential) from the complex Wnt signaling pathway. By isolating and targeting this single upstream regulatory parameter, the invention achieves effective β-catenin translocation control without needing to fully elucidate or intervene in every component of the pathway, thereby reducing research complexity and development time while maintaining treatment specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a novel therapeutic avenue for treating β-catenin-related diseases by modulating β-catenin translocation, potentially reducing cell proliferation in cancers and increasing bone strength in osteoporosis, using existing ion channel and transporter blocking compounds.
Implementation Method 1
using existing ion channel and transporter blocking compounds
Implementation Method 2
modulation of cell membrane electrical potential facilitating β-catenin entry into the nucleus
Implementation Method 3
altering ion transport across the cell membrane
Implementation Method 4
altering ion transport across the cell membrane
Implementation Method 5
The NE acts as a barrier that limits ion and macromolecular exchange into the nucleoplasm
Implementation Method 6
traversing through the NPC by an energy expenditure mechanism such as GTPase Ran/transport receptor pathways
Implementation Method 7
energy expenditure mechanism such as GTPase Ran/transport receptor pathways
Implementation Method 8
a decrease in nucleoplasmic Ca 2+ concentration hyperpolarizes the NE
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to B-catenin, and to the use of compounds which can affect B- catenin translocation within the cell, for use in treating B-catenin/Wnt-signaling- related disorders, such as osteoporosis, cancer or diabetes. The invention extends to pharmaceutical formulations and compositions comprising such compounds.